Short answer
Wave Life Sciences Ltd. (WVE) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2M (down 73.9% year over year) with net income of −$69M.
Q2 2026 key financials · XBRL
- Revenue
- $2M
- −73.9% YoY · −94.1% QoQ
- Net income
- −$69M
- −37.4% YoY · −165.9% QoQ
- Operating margin
- -3248.3%
- EPS (diluted)
- −$0.34
- −9.7% YoY · −161.5% QoQ
Source: XBRL data from the Wave Life Sciences Ltd. (WVE) Q2 2026 10-Q on SEC EDGAR. USD.
Wave Life Sciences Ltd. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and contains no 10-K comparison
- Executive-share-sale risk: CEO plan permits sale of up to 2,924,270 ordinary shares through December 31, 2026
- Insider-selling compliance risk: four officers adopted Rule 10b5-1 plans during the quarter
- Transaction risk: April 15, 2026 implementation agreement filed as Exhibit 2.1
- No liquidity, debt, currency, competitive, operational, or regulatory risk details disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Wave Life Sciences Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.